180 related articles for article (PubMed ID: 16485108)
1. Serum levels of cartilage oligomeric matrix protein (COMP): a rapid decrease in patients with active rheumatoid arthritis undergoing intravenous steroid treatment.
Skoumal M; Haberhauer G; Feyertag J; Kittl EM; Bauer K; Dunky A
Rheumatol Int; 2006 Sep; 26(11):1001-4. PubMed ID: 16485108
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of cartilage oligomeric matrix protein. A predicting factor and a valuable parameter for disease management in rheumatoid arthritis.
Skoumal M; Kolarz G; Klingler A
Scand J Rheumatol; 2003; 32(3):156-61. PubMed ID: 12892252
[TBL] [Abstract][Full Text] [Related]
3. Low serum level of COMP, a cartilage turnover marker, predicts rapid and high ACR70 response to adalimumab therapy in rheumatoid arthritis.
Morozzi G; Fabbroni M; Bellisai F; Cucini S; Simpatico A; Galeazzi M
Clin Rheumatol; 2007 Aug; 26(8):1335-8. PubMed ID: 17285224
[TBL] [Abstract][Full Text] [Related]
4. Decrement of serum cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis (RA) patients achieving remission after 6 months of etanercept treatment: comparison with CRP, IgM-RF, MMP-3 and anti-CCP Ab.
Kawashiri SY; Kawakami A; Ueki Y; Imazato T; Iwamoto N; Fujikawa K; Aramaki T; Tamai M; Nakamura H; Origuchi T; Ida H; Eguchi K
Joint Bone Spine; 2010 Oct; 77(5):418-20. PubMed ID: 20864374
[TBL] [Abstract][Full Text] [Related]
5. Serum cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis and knee osteoarthritis.
Wisłowska M; Jabłońska B
Clin Rheumatol; 2005 Jun; 24(3):278-84. PubMed ID: 15940561
[TBL] [Abstract][Full Text] [Related]
6. [Cartilage oligomeric matrix protein (COMP): the role of a non-collagen cartilage matrix protein as a marker of disease activity and joint destruction in patients with rheumatoid arthritis and osteoarthritis].
Marti C; Neidhart M; Gerber T; Hauser N; Michel BA; Häuselmann HJ
Z Rheumatol; 1999 Apr; 58(2):79-87. PubMed ID: 10408068
[TBL] [Abstract][Full Text] [Related]
7. Serum COMP-C3b complexes in rheumatic diseases and relation to anti-TNF-α treatment.
Happonen KE; Saxne T; Geborek P; Andersson M; Bengtsson AA; Hesselstrand R; Heinegård D; Blom AM
Arthritis Res Ther; 2012 Jan; 14(1):R15. PubMed ID: 22264230
[TBL] [Abstract][Full Text] [Related]
8. Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept.
Crnkic M; Månsson B; Larsson L; Geborek P; Heinegård D; Saxne T
Arthritis Res Ther; 2003; 5(4):R181-5. PubMed ID: 12823852
[TBL] [Abstract][Full Text] [Related]
9. [Evidence of cartilaginous benefit of treatment with infliximab in rheumatoid arthritis using measurement of serum COMP].
Yamamoto M; Takahashi H; Ohara M; Suzuki C; Naishiro Y; Yamamoto H; Shinomura Y; Imai K
Nihon Rinsho Meneki Gakkai Kaishi; 2007 Feb; 30(1):41-7. PubMed ID: 17332704
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of cartilage biomarkers for monitoring structural joint damage in rheumatoid arthritis patients treated with anti-TNF therapy.
Niki Y; Takeuchi T; Nakayama M; Nagasawa H; Kurasawa T; Yamada H; Toyama Y; Miyamoto T
PLoS One; 2012; 7(5):e37447. PubMed ID: 22629396
[TBL] [Abstract][Full Text] [Related]
11. Relations of serum COMP to cardiovascular risk factors and endothelial function in patients with rheumatoid arthritis treated with methotrexate and TNF-α inhibitors.
Hjeltnes G; Hollan I; Førre Ø; Wiik A; Lyberg T; Mikkelsen K; Agewall S
J Rheumatol; 2012 Jul; 39(7):1341-7. PubMed ID: 22660798
[TBL] [Abstract][Full Text] [Related]
12. Cartilage oligomeric matrix protein level in rheumatic diseases: potential use as a marker for measuring articular cartilage damage and/or the therapeutic efficacy of treatments.
Morozzi G; Fabbroni M; Bellisai F; Pucci G; Galeazzi M
Ann N Y Acad Sci; 2007 Jun; 1108():398-407. PubMed ID: 17894003
[TBL] [Abstract][Full Text] [Related]
13. Cytokines, metalloproteinases, their inhibitors and cartilage oligomeric matrix protein: relationship to radiological progression and inflammation in early rheumatoid arthritis. A prospective 5-year study.
Roux-Lombard P; Eberhardt K; Saxne T; Dayer JM; Wollheim FA
Rheumatology (Oxford); 2001 May; 40(5):544-51. PubMed ID: 11371663
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effects of leflunomide therapy on the activity of matrixmetalloproteinase-9 and the release of cartilage oligomeric matrix protein in patients with rheumatoid arthritis.
Kullich WC; Mur E; Aglas F; Niksic F; Czerwenka C
Clin Exp Rheumatol; 2006; 24(2):155-60. PubMed ID: 16762150
[TBL] [Abstract][Full Text] [Related]
15. Early increase in serum-COMP is associated with joint damage progression over the first five years in patients with rheumatoid arthritis.
Andersson ML; Svensson B; Petersson IF; Hafström I; Albertsson K; Forslind K; Heinegård D; Saxne T
BMC Musculoskelet Disord; 2013 Aug; 14():229. PubMed ID: 23915292
[TBL] [Abstract][Full Text] [Related]
16. Cartilage oligomeric matrix protein associates differentially with erosions and synovitis and has a different temporal course in cyclic citrullinated peptide antibody (anti-CCP)-positive versus anti-CCP-negative early rheumatoid arthritis.
Christensen AF; Lindegaard H; Hørslev-Petersen K; Hetland ML; Ejbjerg B; Stengaard-Pedersen K; Jacobsen S; Lottenburger T; Ellingsen T; Andersen LS; Hansen I; Skjødt H; Pedersen JK; Lauridsen UB; Svendsen A; Tarp U; Pødenphant J; Østergaard M; Junker P
J Rheumatol; 2011 Aug; 38(8):1563-8. PubMed ID: 21572145
[TBL] [Abstract][Full Text] [Related]
17. Serum levels of cartilage oligomeric matrix protein (COMP) increase temporarily after physical exercise in patients with knee osteoarthritis.
Andersson ML; Thorstensson CA; Roos EM; Petersson IF; Heinegård D; Saxne T
BMC Musculoskelet Disord; 2006 Dec; 7():98. PubMed ID: 17156423
[TBL] [Abstract][Full Text] [Related]
18. Cartilage oligomeric matrix protein in patients with juvenile idiopathic arthritis: relation to growth and disease activity.
Bjørnhart B; Juul A; Nielsen S; Zak M; Svenningsen P; Müller K
J Rheumatol; 2009 Aug; 36(8):1749-54. PubMed ID: 19605679
[TBL] [Abstract][Full Text] [Related]
19. Cartilage oligomeric matrix protein in serum in systemic lupus erythematosus and knee osteoarthritis. Preliminary communication.
Wisłowska M; Jabłońska B
Rheumatol Int; 2005 Jun; 25(5):373-8. PubMed ID: 15739097
[TBL] [Abstract][Full Text] [Related]
20. [Functional capacity and cartilage oligomeric protein (COMP) in serum of patients with maturity-onset polyarthritis].
Kolarz G; Hermann J; Krajnc I; Palkonyai E; Scherak O; Schödl Ch; Singer F; Temesvari P; Wagner E; Wottawa A
Z Rheumatol; 2002 Aug; 61(4):435-9. PubMed ID: 12426849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
